Navigation Links
Upcoming meeting will explore new technologies for glaucoma clinical drug trials
Date:2/13/2008

Rockville, MD The National Eye Institute (NEI) and the Food and Drug Administration (FDA) are sponsoring a symposium to consider new disease-relevant outcome measures appropriate for evaluating glaucoma therapies.

Currently, clinical drug trials for glaucoma therapies rely on standard perimetric criteria i.e., a vision field test as the primary functional outcome measure.

However, new technologies that assess abnormalities and changes in the optic nerve structure and its function offer vision researchers alternative pathways to better diagnose and treat glaucoma.

This symposium will focus on new outcome measures appropriate for evaluation of glaucoma therapies. The aim is to encourage the development of new glaucoma therapies, facilitate their evaluation and ultimately benefit patients.

Attendees will include:

  • Clinical researchers/basic scientists
  • Clinical trialists
  • Pharmaceutical company representatives
  • Legal/advocacy firms
  • Associations
  • Biotech companies

Registrants will be able to submit questions/comments in advance through a link on their registration confirmation notice.

Glaucoma facts

Glaucoma a potentially blinding but treatable group of diseases affects 2.2 million Americans age 40 and older, resulting in direct medical costs of $2.86 billion annually.

  • Glaucoma robs individuals of peripheral and eventually central vision.
  • Glaucoma is a complex group of neurodegenerative diseases that arises from progressive damage to the optic nerve and retinal ganglion cells and their axons.
  • It is one of the four major aging eye diseases, alongside age-related macular degeneration, diabetic retinopathy and cataracts.
  • About 50 percent of sufferers are unaware they have the disease.
  • Glaucoma disproportionately affects minority populations: It is three times more common in African Americans than in whites and is the leading cause of irreversible vision loss in African Americans and Hispanics.
  • There is a large public health burden from glaucoma due to decreased productivity, reduced independence and diminished quality of life.


'/>"/>

Contact: Lancey Cowan
lcowan@arvo.org
Association for Research in Vision and Ophthalmology
Source:Eurekalert

Related medicine news :

1. Amscot Financial Contributes to the Juvenile Diabetes Research Foundation, Supporting Upcoming Walk for a Cure
2. Align Technology Executives to Present at Upcoming Financial Conferences
3. Nuvelo Announces Upcoming Conference Calls, Webcasts and Conference Participation
4. The Advisory Board Company to Present at Upcoming Conferences
5. Coherent Announces Director Slate for Upcoming Annual Meeting
6. Poniard Pharmaceuticals Announces Upcoming Conference Participation
7. LCA-Vision Announces Upcoming Investment Community Events
8. WellPoint Announces Appearance at Upcoming Conference
9. Thought Leaders in Morbid Obesity Treatment Convene at Upcoming Surgical Conference
10. GSI to Present at Upcoming Investor Growth Conferences
11. WebMD to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... ... they have been diagnosed with endometriosis. These women need a treatment plan to ... a comprehensive approach that can help for preservation of fertility and ultimately achieving ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg ... Legal Elite. The attorneys chosen by their peers for this recognition are considered among ... Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite Hall ...
(Date:6/24/2016)... ... 2016 , ... EB Medicine presented its first-ever “Issue of ... in Ponte Vedra Beach, FL. The awards honor the outstanding work of leading ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the efforts ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
Breaking Medicine Technology: